GAMMA Investing
RNA icon

GAMMA Investing’s Atrium Therapeutics RNA Stock Holding History

GAMMA Investing’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$3.06K Buy
369
+174
+89% +$2.05K ﹤0.01% 3832
2026
Q2 		$2.62K Sell
195
-140
-42% -$1.83K ﹤0.01% 3680
2026
Q1 		$4.48K Buy
+335
New +$4.71K ﹤0.01% 3400

Other funds holding RNA

TC
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
Versant Capital Management
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return
FIA
FNY Investment Advisers New York $402M AUM 85.34% 1-Year Est. Return
EP
Essential Partners Rancho Santa Fe, California $219M AUM 37.92% 1-Year Est. Return
TWD
True Wealth Design Akron, Ohio $426M AUM 16.34% 1-Year Est. Return
FFO
Fortitude Family Office Scottsdale, Arizona $586M AUM 20.58% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

GAMMA Investing's RNA Position: Q3 2026 in Review

GAMMA Investing increased its Atrium Therapeutics (RNA) stake by 89% in Q3 2026, buying an estimated $2.05K and bringing the position to 369 shares worth $3.06K. The position accounts for ﹤0.01% of the portfolio, ranked #3832.

GAMMA Investing first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.48K in Q1 2026. 9 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • GAMMA Investing held 369 shares of Atrium Therapeutics worth $3.06K as of Q3 2026.
  • GAMMA Investing bought 174 Atrium Therapeutics shares in Q3 2026, an estimated $2.05K.
  • Atrium Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3832 holding.
  • GAMMA Investing first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • GAMMA Investing's Atrium Therapeutics position peaked at $4.48K in Q1 2026.
  • 9 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.